Iza-bren + Adagrasib for Lung Cancer

This trial tests a new combination of two drugs, Izalontamab Brengitecan and Adagrasib, to determine if they outperform current treatments for a specific type of lung cancer. It targets individuals with advanced non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation and has not responded to other treatments. This trial may suit those whose lung cancer continues to progress despite using KRAS G12C inhibitors. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.

The trial requires that your most recent systemic therapy, like chemotherapy or immunotherapy, be stopped at least 2 weeks before starting the study drugs. If you are on other medications, the protocol does not specify if they need to be stopped, so it's best to discuss this with the trial team.

Research shows that the combination of Izalontamab Brengitecan (iza-bren) and Adagrasib is under evaluation for safety in patients with advanced lung cancer. Previous studies have primarily assessed how well patients tolerate these drugs together.

Adagrasib has demonstrated promising results in past studies, with patients living about 14.74 months on average, suggesting it is somewhat effective and generally manageable.

Izalontamab Brengitecan, a drug targeting cancer cells, has been effective in 45% of patients in certain studies. While specific side effects weren't detailed, this success rate often indicates reasonable tolerability.

Researchers are excited about the combination of Izalontamab Brengitecan (Iza-bren) and Adagrasib for lung cancer because it brings a fresh approach to treatment. While many existing treatments target specific genetic mutations or use chemotherapy, Adagrasib is a KRAS inhibitor, working directly to block a common mutation driving cancer growth. Meanwhile, Iza-bren, administered intravenously, has shown promise in enhancing the immune system's response to cancer. Together, they offer a novel way to tackle lung cancer by both stopping cancer cell growth and boosting the body's natural defenses.

Research has shown that Adagrasib targets a specific change in the KRAS G12C gene, often found in some lung cancers. This change promotes cancer growth, and Adagrasib works to block it. Studies indicate that Adagrasib can effectively slow tumor growth in patients with this gene change. Izalontamab Brengitecan, a bispecific antibody-drug conjugate, targets two proteins, EGFR and HER3, which are often involved in cancer growth. In this trial, participants will receive a combination of these two drugs to address different ways cancer cells survive. While promising evidence exists for each drug individually, the effectiveness of using them together to treat lung cancer remains under study.¹²³⁶⁷